Publication: 3435

Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN
      QxMD      Google Scholar   
Citation:
Blood Adv vol 5 (4) 1092-6
Year:
2021
Type:
Manuscript
Funding:
AFT
Endpoint:
Secondary
Analysis:
Long-Term-Followup
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
10
Parents:
3402  
Children:
None
Program:
OGC
Primary Committee:
Myeloma
Sec. Committees:
   
Pharmas:
Janssen Oncology  
Grants:
Alliance Foundation Trials  
Corr. Author:
 
Authors:
                           
Networks:
CA043, LAPS-AL002, LAPS-MA036, LAPS-NC007, LAPS-OH007, NC002, NY021   
Study
AFT-29 (GRIFFIN)
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: